M.D.C. (MDC) Downgraded by ValuEngine to “Strong Sell”
ValuEngine lowered shares of M.D.C. (NYSE:MDC) from a sell rating to a strong sell rating in a report published on Friday morning.
A number of other analysts also recently weighed in on the company. Zacks Investment Research downgraded M.D.C. from a buy rating to a hold rating in a research note on Saturday, August 25th. Bank of America upgraded M.D.C. from an underperform rating to a buy rating and lifted their price target for the company from $36.00 to $42.00 in a research note on Thursday, August 2nd. JPMorgan Chase & Co. downgraded M.D.C. from a neutral rating to an underweight rating and decreased their price target for the company from $38.00 to $32.00 in a research note on Friday, September 21st. Finally, Wedbush decreased their price target on M.D.C. from $34.00 to $33.00 and set a neutral rating on the stock in a research note on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $34.43.
Shares of M.D.C. stock traded down $0.50 during trading on Friday, reaching $26.70. The company’s stock had a trading volume of 384,215 shares, compared to its average volume of 555,456. The company has a debt-to-equity ratio of 0.72, a current ratio of 9.59 and a quick ratio of 2.49. M.D.C. has a 12-month low of $26.45 and a 12-month high of $37.45. The company has a market cap of $1.67 billion, a PE ratio of 10.35, a price-to-earnings-growth ratio of 0.43 and a beta of 1.43.
In other M.D.C. news, Chairman Larry A. Mizel sold 10,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $33.15, for a total transaction of $331,500.00. Following the sale, the chairman now directly owns 121,867 shares in the company, valued at $4,039,891.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Larry A. Mizel sold 20,000 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $32.62, for a total value of $652,400.00. Following the sale, the chairman now owns 131,867 shares in the company, valued at $4,301,501.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,000 shares of company stock worth $1,637,300. 27.00% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of MDC. MUFG Americas Holdings Corp purchased a new stake in M.D.C. during the second quarter worth $106,000. Sun Life Financial INC purchased a new stake in M.D.C. during the second quarter worth $140,000. Xact Kapitalforvaltning AB purchased a new stake in M.D.C. during the first quarter worth $203,000. Amalgamated Bank purchased a new stake in M.D.C. during the second quarter worth $204,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of M.D.C. in the second quarter valued at $214,000. Institutional investors own 77.54% of the company’s stock.
M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.
Further Reading: How to calculate the intrinsic value of a stock
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.